Peptide-T

Summary

Peptide‑T (also called D‑Ala‑Peptide T‑amide or DAPTA) is an investigational peptide derived from the HIV‑1 envelope that has been explored as an immunomodulatory agent, notably for HIV‑associated dementia. It is studied in research settings via intranasal, intravenous or subcutaneous delivery, but it has not received regulatory approval for any indication.

Mechanism of Action

The peptide is thought to interact with the trimolecular complex formed by major histocompatibility complex class II molecules, bound peptide, and the T‑cell receptor (MHC‑II‑p‑TCR). By fitting into the peptide‑binding groove and presenting a specific orientation toward the TCR, Peptide‑T may modulate T‑cell activation and downstream immune responses. This concept is discussed in reviews of peptide‑based vaccine design and of the fate of MHC‑peptide‑TCR complexes during activation.

What the Research Shows

The literature on Peptide‑T is limited to reviews and early‑phase observations. A 1997 pharmacotherapy review noted that Peptide‑T was among several agents investigated for HIV‑associated dementia, but the evidence consisted mainly of open, uncontrolled trials and case reports, precluding firm conclusions. Subsequent immunological reviews (2022) described design principles for peptide epitopes that engage MHC‑II‑TCR complexes, citing Peptide‑T as an example of a neuropeptide derived from the HIV envelope. A 1995 study on MHC‑peptide‑TCR dynamics provided mechanistic insight that underpins the hypothesized immunomodulatory action of such peptides. No controlled clinical trials or definitive efficacy data were reported.

Reported Benefits

Preliminary investigations suggest Peptide‑T may have neuroprotective or cognitive‑enhancing effects in patients with HIV‑associated dementia, based on limited case series and uncontrolled observations. Its ability to engage MHC‑II‑TCR complexes raises the possibility of broader immunomodulatory benefits, although these remain speculative.

Limitations of the Evidence

Evidence is confined to small, uncontrolled studies and theoretical immunological models; no randomized controlled trials have been published. The therapeutic impact on HIV‑dementia or other conditions has not been established, and the peptide’s efficacy, optimal dosing, and comparative advantage over existing treatments are unknown.

Safety Considerations

The abstracts do not provide specific adverse‑event data for Peptide‑T. As an investigational compound, its safety profile in humans is not well characterized. Caution is advised because unknown toxicities, immunogenicity, or off‑target effects may exist, and the peptide is not approved for clinical use.

How It Is Administered

Peptide‑T has been studied for delivery by intranasal, intravenous, and subcutaneous routes. Formulations are not detailed in the cited literature; administration is limited to research protocols.

Routes of Administration

Goals & Uses

• PsoriasisDermatology / InflammatoryLow
• NeuroprotectionNeurologyLow
• Anti-HIV / blocking viral entryAntiviralLow
• HIV-associated neurocognitive disorders (HAND) / AIDS dementia complexNeurological / AntiviralLow
• CCR5 antagonism / anti-inflammatoryImmunologicalLow

Contraindications

• Hypersensitivity to Peptide-T or its componentsAllergy / ImmunologicalHigh
• PregnancyPopulationModeratePotential fetal risk or insufficient safety data

Adverse Effects

• Injection site reactionsLocalUncommon
• HeadacheNeurologicUncommonPain in the head or upper neck
• FatigueGeneralUncommonLow energy or tiredness
• Nasal irritation / rhinorrheaLocal / IntranasalCommon

Drug Interactions

• Antiretroviral agents (e.g., CCR5 antagonists such as maraviroc)Low
• ImmunosuppressantsLowPotential interaction with immune pathways or infection risk

Population Constraints

• Severe renal or hepatic impairmentOrgan FunctionRelative
• Pediatric patientsAgeRelative
• Pregnant or breastfeeding womenReproductiveRelative

Regulatory Status

• European UnionUnapprovedNo EMA marketing authorization. Research use only.
• United StatesInvestigationalInvestigated under IND in Phase I/II trials (1980s–1990s) for HIV-associated neurological disease. Never approved by the FDA.
• United KingdomUnapprovedNo MHRA approval. Research use only.

Never received FDA, EMA, or MHRA approval. Investigated in Phase I/II clinical trials in the late 1980s–1990s. Not commercially available as a licensed medicine; available only through research channels.

Evidence & Sources

• Stereo electronic principles for selecting fully-protective, chemically-synthesised malaria vaccines
  Journal ArticleModeratePatarroyo ME, et al.2022-01-01T00:00:00.000000Z
• Pharmacotherapy of HIV dementia
  Journal ArticleModerateMelton ST, Kirkwood CK, Ghaemi SN1997-01-01T00:00:00.000000Z
• Fate of intercellular MHC-peptide-T-cell receptor complexes during T-cell activation
  Journal ArticleModerateClark BR1995-01-01T00:00:00.000000Z
• Prevention of type 1A diabetes mellitus
  Journal ArticleModerateEisenbarth GS2012-01-01T00:00:00.000000Z

Frequently Asked Questions